Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 From Ambiguity to Action: The FDA’s New Nitrosamine Guidance | Contract Pharma

What are you searching for?

Sign in

From Ambiguity to Action: The FDA’s New Nitrosamine Guidance

Nitrosamine contamination in pharmaceutical products has become a critical concern within the industry due to the potential carcinogenic risks these impurities pose. The U.S. Food and Drug Administration (FDA) has taken an active role in addressing these concerns, issuing warnings about the risks associated with Nitrosamine Drug Substance-Related Impurities (NDSRIs). New guidance from the FDA provides a clearer path forward for drug manufacturers, including strategies for lobbying alternative limits and demonstrating bioequivalence when using nitrite scavengers.

In this webinar, we'll break down the FDA’s newly finalized guidance and discuss both established and emerging techniques to reduce nitrosamine formation in your products and stay compliant.

Key Objectives:
  • Gain a comprehensive understanding of the latest regulatory updates
  • Identify which products are most vulnerable to nitrosamine contamination
  • Explore both proven and innovative strategies for mitigating nitrosamine risks
Speaker:

Jason Brown
Senior Manager, Analytical Sciences, R&D, Adare Pharma Solutions

Register Now!
PRESENTED BY:
Warning: Undefined variable $featured_post in /var/www/html/wp-content/themes/RodmanMediaCore/single-webinar.php on line 216 Warning: Attempt to read property "ID" on null in /var/www/html/wp-content/themes/RodmanMediaCore/single-webinar.php on line 216